Semaglutide reduces major adverse cardiovascular events (MACE) independently of weight loss.

[Correspondence] Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00255-2/fulltext?rss=yes In prespecified analyses from the SELECT trial, semaglutide reduced major adverse cardiovascular events (MACE) compared with placebo, with only about one-third of benefit mediated by waist circumference change.1 John Deanfield and colleagues report…

[Correspondence] Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial – Authors' reply www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00706-3/fulltext?rss=yes We thank Justin Tondt and Vernon M Chinchilli for their comments on our analyses of the relationship between adiposity measures and major adverse cardiovascular event (MACE) benefit from semaglutide in the SELECT trial. To explore evidence for weight…

[Correspondence] Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00256-4/fulltext?rss=yes John Deanfield and colleagues reported that semaglutide reduces major adverse cardiovascular events (MACE) independent of weight loss.1 However, this conclusion relies on conditioning on a post-randomisation mediator (weight loss), which is a method known…